UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2026

 

Commission File Number: 001-41752

 

Perpetuals.com Ltd

 

5-7-11, Ueno, Taito-ku

Tokyo, Japan 110-0005

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒        Form 40-F ☐

 

 

 

Explanatory Note

 

Perpetuals.com Ltd (the “Company”) issued a press release on April 22, 2026, announcing the extension of its proprietary BayesShield AI technology into healthcare. A copy of this press release is attached hereto as Exhibit 99.1, and is incorporated by reference herein.

 

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Perpetuals (NASDAQ: PDC) Extends BayesShield AI Into Healthcare to Address the Root Cause of Diagnostic Errors

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Perpetuals.com Ltd
Date: April 22, 2026	By:	/s/ Satoshi Kobayashi
	Name:	Satoshi Kobayashi
	Title:	Co-Chief Executive Officer, Interim Chief Financial Officer and Representative Director
		(Principal Executive Officer)

 

 

ATTACHMENTS / EXHIBITS

PERPETUALS (NASDAQ: PDC) EXTENDS BAYESSHIELD AI INTO HEALTHCARE TO ADDRESS THE ROOT CAUSE OF DIAGNOSTIC ERRORS

SEC Filings